Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Equities researchers at Jefferies Financial Group dropped their Q1 2021 earnings per share estimates for Supernus Pharmaceuticals in a report released on Tuesday, April 13th. Jefferies Financial Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will post earnings of $0.30 per share for the quarter, down from their previous estimate of $0.31. Jefferies Financial Group currently has a “Buy” rating and a $40.00 target price on the stock. Jefferies Financial Group also issued estimates for Supernus Pharmaceuticals’ Q2 2021 earnings at $0.21 EPS, Q3 2021 earnings at $0.12 EPS, Q4 2021 earnings at $0.26 EPS and FY2021 earnings at $0.90 EPS.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Thursday, February 25th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, meeting the consensus estimate of $0.57. Supernus Pharmaceuticals had a return on equity of 20.02% and a net margin of 27.09%. The business had revenue of $143.56 million for the quarter, compared to the consensus estimate of $145.52 million.
Several other brokerages have also commented on SUPN. TheStreet upgraded Supernus Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Tuesday, January 5th. Piper Sandler boosted their price objective on Supernus Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Wednesday, February 3rd. Finally, Zacks Investment Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $31.75.
Shares of SUPN opened at $31.85 on Wednesday. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of 13.22 and a beta of 1.38. The stock has a 50 day moving average of $26.87 and a 200-day moving average of $24.95. The company has a current ratio of 1.84, a quick ratio of 1.70 and a debt-to-equity ratio of 0.53. Supernus Pharmaceuticals has a 52 week low of $17.20 and a 52 week high of $32.31.
In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 3,125 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, April 14th. The stock was sold at an average price of $31.98, for a total transaction of $99,937.50. Following the sale, the vice president now owns 89,451 shares of the company’s stock, valued at approximately $2,860,642.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.57% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Scout Investments Inc. grew its stake in Supernus Pharmaceuticals by 8.4% in the fourth quarter. Scout Investments Inc. now owns 289,028 shares of the specialty pharmaceutical company’s stock valued at $7,272,000 after purchasing an additional 22,488 shares in the last quarter. Sei Investments Co. grew its stake in Supernus Pharmaceuticals by 10.5% in the third quarter. Sei Investments Co. now owns 240,862 shares of the specialty pharmaceutical company’s stock valued at $5,020,000 after purchasing an additional 22,831 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Supernus Pharmaceuticals in the third quarter valued at about $760,000. Voloridge Investment Management LLC grew its stake in Supernus Pharmaceuticals by 4.8% in the third quarter. Voloridge Investment Management LLC now owns 149,800 shares of the specialty pharmaceutical company’s stock valued at $3,122,000 after purchasing an additional 6,799 shares in the last quarter. Finally, HealthInvest Partners AB purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $11,699,000. Institutional investors and hedge funds own 96.11% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
See Also: Why Invest in Dividend Achievers?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.